NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced the pricing of a registered public offering of shares of common stock and warrants to purchase common stock. In connection with the public offering, the Company entered into agreements with investors to sell approximately 19.8 million shares of its common stock at a price per share of $0.29, representing gross proceeds of approximately $5.75 million. Net proceeds to BrainStorm, after deducting fees to the placement agent and other offering expenses, are expected to be approximately $4.78 million.
